Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.02.9099.4750
Address
Level 1 3-5 George Street Leichardt, New South Wales (NSW) 2040
Description
Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.04
Trade Value (12mth)
AU$2,266.00
1 week
-10.53%
1 month
-10.53%
YTD
-12.82%
1 year
-39.29%
All time high
0.63
EPS 3 yr Growth
0.90%
EBITDA Margin
-134.60%
Operating Cashflow
-$5m
Free Cash Flow Return
-37.60%
ROIC
-54.90%
Interest Coverage
-577.90
Quick Ratio
4.80
Shares on Issue (Fully Dilluted)
639m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 May 25 |
Update - Proposed issue of securities - AT1
×
Update - Proposed issue of securities - AT1 |
05 May 25 |
Application for quotation of securities - AT1
×
Application for quotation of securities - AT1 |
05 May 25 |
Notification regarding unquoted securities - AT1
×
Notification regarding unquoted securities - AT1 |
05 May 25 |
Notification of cessation of securities - AT1
×
Notification of cessation of securities - AT1 |
05 May 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
05 May 25 |
Initial Director's Interest Notice x 2
×
Initial Director's Interest Notice x 2 |
05 May 25 |
Final Director's Interest Notice x 3
×
Final Director's Interest Notice x 3 |
24 April 25 |
Atomo completes Capital Raise and undertakes Restructure
×
Atomo completes Capital Raise and undertakes Restructure |
24 April 25 |
Proposed issue of securities - AT1
×
Proposed issue of securities - AT1 |
24 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 April 25 |
Notification of cessation of securities - AT1
×
Notification of cessation of securities - AT1 |
23 April 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
23 April 25 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
22 April 25 |
Trading Halt
×
Trading Halt |
07 April 25 |
National Scale up of HIV Self-Test Vending Machines
×
National Scale up of HIV Self-Test Vending Machines |
24 March 25 |
Pause in Trading
×
Pause in Trading |
24 March 25 |
Suspension from Quotation
×
Suspension from Quotation |
24 March 25 |
Exclusive Licence for Novel Syphilis Test on Pascal Secured
×
Exclusive Licence for Novel Syphilis Test on Pascal Secured |
24 March 25 |
Reinstatement to Quotation
×
Reinstatement to Quotation |
28 February 25 |
Appendix 4D and Half Year Report ended 31 Dec 2024
×
Appendix 4D and Half Year Report ended 31 Dec 2024 |
28 February 25 |
H1 FY25 Results Presentation
×
H1 FY25 Results Presentation |
26 February 25 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 January 25 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
14 January 25 |
Atomo Secures Long Term Agreement with Newfoundland
×
Atomo Secures Long Term Agreement with Newfoundland |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.